Comparison study between insulin glargine and decludec on the glucose fluctuation in Type 2 diabetic patients treated with basal insulin and oral hypoglycemic agents.

Comparison study between insulin glargine and decludec on the glucose fluctuation in Type 2 diabetic patients treated with basal insulin and oral hypoglycemic agents. - Comparison study between insulin glargine and decludec on the glucose fluctuation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012138

Enrollment

Registered

2013-10-28

Start date

2013-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients

Interventions

insulin glargine insulin decludec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2 MD treated with insulin glargine and oral hypoglycemic agents(HbA1c; over than 6.5%)

Exclusion criteria

Exclusion criteria: patients with liver or renal dysfunction and obese patienst(BMI over than 35)

Design outcomes

Primary

Measure	Time frame
CGM(glucose average, SD, MAGE) and Endo-pat	—

Countries

Japan

Contacts

Public ContactYoshikazu Sumitani

Kyorin University of Medicine Third Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism

sumitani@ks.kyorin-u.ac.jp024-247-5512

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026